Chronic fatigue syndrome

Townsend Letter for Doctors and Patients, Feb-March, 2004 by Charles Weber

When surgery is necessary for CFS patients it is imperative that doctors become familiar with contraindications for medication because CFS patients are very susceptible to adverse reactions from some anesthetics and other medications [http://www.sonic.net/~melissk/anesthesia.html].

CFS is potentially extremely dangerous to society because of its severity and length of recovery time. If a mosquito ever learns how to transmit it, the situation will be desperate for society. Therefore enormous research effort should be mobilized to not just ameliorate it, but like smallpox, to eradicate it.

Correspondence:

The Arthritis Trust of America

7376 Walker Road

Fairview, Tennessee 37062-8141 USA

615-799-1002 (phone/fax)

www.arthritistrust.org

administration@arthritistrust.org

Bibliography

Anonymous. 1994. Potassium and sodium and potassium in the skeletal muscle. Laeger Ugeskr 156; 4007-4010.

Bell DS, Bell KM, Cheney PR. 1994. Primary juvenile fibromyalgia syndrome and chronic fatigue syndrome in adolescents. Clin. Infect. Dis. Suppl. 1;S21-3.

Bell IR, Baldwin CM, Schwartz GE. 1998. Illness from low levels of environmental chemicals: relevance to chronic fatigue syndrome and fibromyalgia. Am. J. Med. 105; 74S-82S.

Buchwald D, Sullivan JL, Leddy S, Komaroff AL. 1988. "Chronic Epstein-Barr virus infection" syndrome and polymyalgia rheumatics. J. Rheumatol. 15;479-82.

Biddle R. et al. 1992. A chronic illness characterized by fatigue, neurologic and immunologic disorders, and active human herpes virus type 6 infection. Annals of Internal Medicine 116;103-13.

Burnet RB, Yeap BB, Chatterton BE, Gaffney RD. 1996. Chronic fatigue syndrome: is total body potassium important? Med. J. Aust. 164;384.

Caligiuri M, Murray C, Buchwald D, Levine H, Cheney P, Peterson D, Komaroff AL, Ritz J. 1987. Phenotypic and functional deficiency of natural killer cells in patients with chronic fatigue syndrome. J. Immunol 139(10):3306-13.

Cannon JG, Angel JB, Abad LW, Vannier E, Mileno MD, Fagioli L, Wolff, SM, Komaroff AL. 1997. Interleukin-1 beta, interleukin-1 receptor antagonist, and soluble interleukin-1 receptor type II secretion in chronic fatigue syndrome. J. Clin. Immunol 17;253-261.

Charalampous FC. 1971. Metabolic functions of myoinositol: VIII - role of inositol in Na -K transport an in Na and K activated adenosine triphosphate of KB cells. Journal of Biol. Chem. 246;455 & 456.

Clapp LL, Richardson MT, Smith JF, et al. Acute effects of 30 minutes of light-intensity, intermittent exercise on patients with chronic fatigue syndrome. Phys. Ther. 1999;79:749-56.

Coutts R, Weatherby R, Davie A. 201. The use of a symptom "self report" inventory to evaluate the acceptability and efficiency of a walking program for patients suffering with chronic fatigue syndrome. J. Psychosom. Res. 51;425-29.

Cox IM, Campbell MJ, Dowson D. 1991. Red blood cell magnesium and chronic fatigue syndrome. Lancet Mar 30;337(8744):757-60.

Demitrack MA, Dale JK, Straus SE, Laue L, Listwak SJ, Kruesi MJ, Chrousos GP, Gold PW. 1991. Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome. J. Clin Endocrinol. Metab. 73(6):1224-34.